Penn Medicine Provider
Hematology
Keith W. Pratz, MD
4.9
(322)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Director, Leukemia Program
  • Section Chief, Leukemia, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: Mayo Clinic
  • Fellowship: Johns Hopkins Hospital

What my patients think about me

Average Rating
4.9

322 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
is an excellent doctor
April 2025
5.0
5.0
have great faith in dr. pratz
April 2025
5.0
5.0
dr pratz is very informed and supportive.
April 2025
5.0
5.0
always explains things very well i feel good after talking to him

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Pratz is a Penn Medicine physician.

Qualifications and experience

My research

Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544


Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation , Transplantation and Cellular Therapy: 2025


Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025


Pratz KW, Erba HP. Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents , Am J Hematol: 2025


Pratz KW. Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1 , Br J Haematol: 2024


DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia , Am J Hematol: 2024


Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia , Haematologica, 109(8): 2024,2732-2737


12., Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D Ven the dose matters: Venetoclax dosing in the frontline treatment of AML , Blood Rev: 2024


Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine , Blood: 2024


Hamilton KW, Hua E, Dutcher L, Fernandez Lynch H, Junker P, Doucette AG, Werner D, Kannel EZ, Civitello T, Gabriel P, Ahya VN, Jacobs DA, Garfall A, Pratz K, Degnan KO, Blumberg EA, Capozzi D, Craig E, Takach P, Payne AS, Geara A, Koenig H, Holzman L, Tebas P Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center , Open Forum Infect Dis., 11(8): 2024